Most lung cancers are diagnosed once they are at a late stage1

  • Lung cancer tends to be diagnosed when symptoms become apparent; by this time the tumor is often at an advanced stage (III & IV)
  • Over 50% of all patients die within 12 months of diagnosis
  • Early diagnosis more than triples the 5-year survival rate to 56% if the tumor is found localized, but unfortunately only 16% of lung cancer are diagnosed while still localized2

Diagnosing lung cancer early saves lives

  • Annual CT screening of high risk patients has demonstrated a 20% reduction in lung cancer mortality thanks to early stage detection2
  • Annual CT screening is only recommended as a screening test in the US for patients with strictly defined risk factors: age 55+ with 30 or more smoking pack years, current smoker or cessation within last 15 years4

EarlyCDT-Lung test can detect autoantibodies to lung cancer 4 years or more before symptoms present5,6.

Howlader N, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017
2 SEER Cancer Stat Facts: Lung and Bronchus Cancer. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/lungb.htm l
3 The National Lung Screening Trial Research Team.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med 2011; 365:395-409.
4 Final Update Summary: Lung Cancer: Screening. U.S. Preventive Services Task Force. July 2015. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening
5 Zhong L, et al. Profiling tumour-associated antibodies for early detection of non-small cell lung cancer. J Thor Oncol 2006; 1:513-519.
6 Jett J, et al. Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. J Thor Oncol 2017; 12(11):S2170.


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept